FilingFirehose · custom report

SEM — SELECT MEDICAL HOLDINGS CORP

SEC filings analysis · 5 filings reviewed (last 12 months) · generated 2026-07-06 14:21 UTC

Executive summary

SELECT MEDICAL HOLDINGS CORP filed five 8-K reports over the past 12 months, with the most significant being a July 2026 filing (accession 0001104659-26-079643) containing material acquisition-related items (1.01, 2.01, 2.03) alongside multiple corporate governance and securities amendments (items 3.01, 3.03, 5.01, 5.02, 5.03). The filing pattern suggests active M&A or restructuring activity, though the provided data lacks detailed dollar amounts and transaction specifics. No ATM shelf offerings or dilutive equity financing were detected across the filings analyzed.

Dilution risk 1/5

No evidence of active dilution or equity issuance detected in the five 8-K filings reviewed. Item 2.02 (results of operations) and Item 5.07 (submission of matters to vote) appear in multiple filings but do not indicate new equity authorization or offerings. The absence of Item 3.02 (unregistered sales) or Item 5.02 (costs associated with exit/disposal) related to equity suggests minimal near-term dilution risk from the filings analyzed.

No ATM shelf offerings identified across accessions 0001104659-26-053056, 0001104659-26-048634, 0001104659-26-079643, 0001104659-26-078332, 0001104659-26-076085
Absence of Item 3.02 (unregistered sales of equity) in all five filings
Item 2.02 and 5.07 disclosures do not reference new equity issuance

Notable filings (5)

2026-07-01 8-K	Material acquisition or business combination with amendments to articles of incorporation and multiple securities-related disclosures · filing The filing indicates a major corporate transaction involving acquisition or merger activity (items 1.01, 2.01, 2.03), coupled with bylaw amendments (items 3.01, 3.03) and new or amended securities instruments (items 5.01, 5.02, 5.03). The nested item relationships suggest comprehensive restructuring or M&A completion. Investors should seek the full 8-K text for transaction size, counterparty, and financing terms.
2026-06-26 8-K	Costs associated with exit or disposal activities disclosed alongside regulation FD disclosure · filing Item 5.07 (submission of matters to vote) combined with the buried JSON reference to Item 1.01 suggests stakeholder approval may have been required for exit or disposal costs. Item 7.01 (regulation FD) indicates material non-public information was disclosed. This may signal workforce reduction, facility closure, or divestiture activity.
2026-06-22 8-K	Other events disclosure with potential relationship to undisclosed material activity · filing Item 8.01 (Other) filed as the sole disclosure item, yet the buried JSON links this to Item 1.01, suggesting the filer reported under 8.01 while the body language indicates a material agreement or transaction. This indirect disclosure approach warrants scrutiny of the full filing text.
2026-04-30 8-K	Costs associated with exit or disposal activities and amendment to material contracts · filing Items 2.02 (results) and 5.02 (costs of exit/disposal) suggest operational challenges or strategic retrenchment. The April timing may indicate Q1 2026 results disclosure with restructuring charges. Item 9.01 (financial statements and exhibits) indicates supporting documentation filed.
2026-04-24 8-K	Costs associated with exit or disposal activities submitted to stockholder vote · filing Item 5.07 (submission of matters to vote) combined with Item 9.01 (exhibits) suggests stockholder approval was sought for material exit or disposal activities. This indicates significant operational changes requiring shareholder consent.

Financing activity

No ATM shelf offerings, debt issuances, or equity offerings are evident from the five 8-K filings analyzed. The July 2026 filing references amendments to securities instruments (items 5.01, 5.02, 5.03) but without supporting data detailing the nature or size of such amendments. No 424B5 prospectus supplements or shelf capacity information was identified.

Risk signals

Multiple exit or disposal cost disclosures (April 24 and April 30, 2026) suggest ongoing operational restructuring or divestiture activity; investors should obtain full 8-K exhibits to quantify financial impact and identify affected business segments.
July 1, 2026 filing contains 10 separate items including acquisition (1.01), business combination (2.01, 2.03), and bylaw amendments (3.01, 3.03), indicating major structural change; lack of specific transaction details in provided data creates visibility gap regarding enterprise value impact and integration risks.
Item 8.01 (Other) disclosure on June 22 was cross-referenced to Item 1.01 via buried JSON, suggesting the company may have reported under a catch-all category rather than the most specific item—potential indicator of disclosure drafting issues or lack of transparency clarity.
April 30 filing links costs of exit/disposal (5.02) to material contracts (2.02), implying operational headwinds may be tied to vendor, customer, or employment agreements; investors should review 10-Q/10-K for context on revenue concentration and contract terms.
Absence of Item 3.02 (unregistered sales) or Item 8.01 (other events) discussions tied to new equity or warrant issuance does not rule out dilution from prior-period equity awards or deferred compensation plans; review proxy statements and equity footnotes in 10-Q/10-K for stock option and RSU acceleration risks.
Five 8-K filings in 12 months with emphasis on amendments, votes, and exit activities suggests heightened corporate governance or strategic volatility; investors should cross-reference with 10-K MD&A for management commentary on strategic direction and competitive positioning.

Bottom line

Given the filing evidence, an investor should obtain and review the full text of the July 1, 2026 8-K (accession 0001104659-26-079643) to understand the scope and financing structure of the apparent M&A or restructuring event, and should cross-reference the April 2026 exit/disposal cost disclosures with the company's most recent 10-Q to quantify the financial impact and timeline of operational changes. The pattern of multiple governance and cost-related filings warrants careful monitoring of subsequent quarterly filings for evidence of revenue disruption, margin pressure, or additional charges related to the disclosed restructuring activities.

View this report online